Valinomycin

Summary

Valinomycin is a cyclic depsipeptide ionophore antibiotic originally isolated from Streptomyces species. In research settings it is employed primarily as a potassium‑selective ion carrier to manipulate membrane potentials, and it displays in‑vitro antimicrobial and antiparasitic activity against organisms such as Leishmania and Trypanosoma. The compound is not approved for therapeutic use and is investigated chiefly as a biochemical tool.

Mechanism of Action

Valinomycin forms a highly selective complex with K⁺ ions, shielding the charge and allowing the ion to traverse lipid bilayers. By collapsing K⁺ gradients it alters membrane potential, drives K⁺ efflux, and can trigger downstream cellular events such as cell shrinkage and eryptosis. Its ion‑transport activity underlies both its utility in electrophysiological assays and its cytotoxic effects.

What the Research Shows

The literature describes valinomycin as a non‑ribosomal peptide produced by a dedicated NRPS gene cluster in Streptomyces, with a cyclododecadepsipeptide scaffold. Structural reviews detail its K⁺‑selective ionophore function, which is exploited in optical‑probe assays of membrane potential and in studies of gastric H⁺,K⁺‑ATPase activity. Biological surveys report antimicrobial activity, notably against Leishmania and Trypanosoma species, and identify it as a trigger of eryptosis in erythrocytes via K⁺ loss and calcium‑dependent pathways. Biosynthetic investigations continue to explore gene clusters and heterologous expression for future engineering.

Reported Benefits

Valinomycin provides a powerful, highly selective tool for experimentally manipulating intracellular K⁺ concentrations, enabling precise measurement of ion transport and membrane potential in vitro. Its demonstrated in‑vitro activity against certain parasites and bacteria suggests potential as a lead compound for antimicrobial development, and its ability to induce eryptosis offers a model for studying red‑cell death mechanisms.

Limitations of the Evidence

Evidence for therapeutic benefit is limited to laboratory studies; no clinical trials or regulatory approval exist. Antimicrobial activity has been reported only in vitro, and potency, spectrum, and pharmacokinetics remain undefined. Its ion‑ophoric nature causes cytotoxicity at concentrations that disrupt normal K⁺ homeostasis, limiting translational applicability. Further in‑vivo efficacy and safety data are lacking.

Safety Considerations

Because valinomycin shuttles K⁺ across membranes, it can rapidly disturb cellular ion balance, leading to cell shrinkage, membrane phosphatidylserine exposure, and programmed erythrocyte death (eryptosis). These effects raise concerns for hemolysis and broader cytotoxicity. Laboratory handling should follow standard safety procedures for ionophores, and its use is confined to controlled research environments where dosing can be rigorously monitored.

How It Is Administered

In research protocols valinomycin is administered intravenously or applied topically as a solution, often dissolved in organic solvents compatible with cell culture or physiological buffers. Formulations are typically prepared fresh for each experiment to ensure activity and avoid degradation.

Routes of Administration

Goals & Uses

• Antimicrobial activityAnti InfectiveLow
• Anticancer activityOncologyLow
• Antiviral activity (SARS-CoV)AntiviralLow
• Ion channel / transport researchBasic ResearchHigh
• Research tool – membrane potential studiesBasic ResearchHigh
• Potassium ionophore researchResearch ToolHigh
• Antimicrobial screeningResearch ToolModerate

Contraindications

• Human therapeutic administrationClinical UseHigh
• Renal impairmentOrgan DysfunctionHigh
• Cardiac arrhythmia riskCardiovascularHigh

Adverse Effects

• Mitochondrial uncouplingMetabolicCommon
• Hyperkalemia / hypokalemiaElectrolyte DisturbanceUnknown
• Apoptosis inductionCellular ToxicityCommon
• HemolysisHematologicUncommon
• CytotoxicityCell ViabilityCommon

Drug Interactions

• Cardiac glycosides (e.g., digoxin)High
• Mitochondrial complex inhibitors (e.g., rotenone)High
• Potassium-sparing diureticsHigh

Population Constraints

• All human populations (therapeutic use)GeneralAbsolute
• Pediatric patientsAgeAbsolute
• Patients with cardiac diseaseCardiovascularAbsolute
• Pregnant individualsReproductiveAbsolute

Regulatory Status

• European UnionUnapprovedNo marketing authorization; sold as a laboratory reagent
• United StatesUnapprovedNot FDA‑approved; available only for research
• United KingdomUnapprovedNot licensed for medicinal use

Not approved by FDA, EMA, or any major regulatory authority for human therapeutic use. Used exclusively as a laboratory research reagent. Some interest in repurposing as an antiviral or anticancer agent remains at the preclinical stage.

Evidence & Sources

• Biosynthesis of depsipeptides, or Depsi: The peptides with varied generations
  Journal ArticleModerateAlonzo DA, Schmeing TM2020-01-01T00:00:00.000000Z
• Erythrocyte programmed cell death
  Journal ArticleModerateFöller M, Huber SM, Lang F2008-01-01T00:00:00.000000Z
• The Nonribosomal Peptide Valinomycin: From Discovery to Bioactivity and Biosynthesis
  Journal ArticleModerateHuang S, et al.2021-01-01T00:00:00.000000Z
• Electrophysiology of plasma membrane vesicles
  Journal ArticleModerateWright EM1984-01-01T00:00:00.000000Z
• Bioprospecting Sponge-Associated Microbes for Antimicrobial Compounds
  Journal ArticleModerateIndraningrat AA, Smidt H, Sipkema D2016-01-01T00:00:00.000000Z
• The gastric H+,K(+)-ATPase
  Journal ArticleModerateWallmark B, Lorentzon P, Sachs G1990-01-01T00:00:00.000000Z

Frequently Asked Questions